Discontinued — last reported Q4 '24
Products & Services · Revenue, remaining performance obligation
Oncology — Revenue, remaining performance obligation
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ4 2024
Last reportedQ4 2024
Rolls up toDeferred Revenue
How to read this metric
An increase indicates a growing backlog of contracted oncology services, suggesting strong future demand and revenue visibility. A decrease may signal that the company is fulfilling contracts faster than it is signing new ones or that there is a slowdown in new contract acquisition.
Detailed definition
This metric represents the total transaction price allocated to oncology-related performance obligations that are unsati...
Peer comparison
Comparable to 'Deferred Revenue' or 'Backlog' metrics reported by other diagnostic and life sciences companies with long-term service agreements.
Metric ID:
ntra_segment_oncology_revenue_remaining_performance_obligationHistorical Data
1 periods
| Q4 '24 | |
|---|---|
| Value | $20.00M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Natera, Inc.'s oncology — revenue, remaining performance obligation?
- Natera, Inc. (NTRA) reported oncology — revenue, remaining performance obligation of $20.00M in Q4 2024.
- What does oncology — revenue, remaining performance obligation mean?
- The total value of oncology service contracts that have been signed but not yet fulfilled or recognized as revenue.